Risk of Diabetes in Young Turner Syndrome Patients

Turner Syndrome is a common genetic disorder. Seventy percent of adults with Turner Syndrome have abnormalities in glucose metabolism which can lead to diabetes. The current screening guidelines for diabetes in Turner Syndrome are not specific and involve a fasting blood sugar once a year. The objective of this study is to determine if there are abnormalities in glucose metabolism and pancreatic function in young girls with Turner Syndrome. The study hypothesis is that pancreatic dysfunction (specifically of the beta cells that make insulin) is more prevalent in girls with Turner Syndrome compared to healthy controls.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Turner Syndrome Cardiovascular Abnormalities Cardiovascular Diseases Chromosome Disorders Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diabetes Mellitus Disorders of Sex Development Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genetic Diseases, Inborn Glucose Metabolism Disorders Gonadal Disorders Gonadal Dysgenesis Heart Defects, Congenital Heart Diseases Male Urogenital Diseases Metabolic Diseases Nutritional and Metabolic Diseases Sex Chromosome Disorders Sex Chromosome Disorders of Sex Development Urogenital Abnormalities Urogenital Diseases

Age range

6 year–22 year

Sex eligibility

Female

Study type

Observational

Primary location

Children's Hospital Medical Center, Cincinnati

Cincinnati, Ohio, 45229, United States

About this study

The study will be conducted at Children's Hospital Medical Center, Cincinnati. The study will require 1 visit to the hospital where the subject will have an oral glucose tolerance test and a physical exam

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Turner Syndrome Females:

Inclusion criteria

Turner Syndrome confirmed by chromosomal testing
On standard therapy (growth hormone and or estrogen)

Exclusion criteria

Type 1 or Type 2 diabetes
Polycystic Ovarian Syndrome
Pregnancy
On any medications that alter blood sugar

Healthy Female Controls:

Inclusion criteria

Healthy

Exclusion criteria

Type 1 or Type 2 diabetes
Polycystic Ovarian Syndrome
Pregnancy
On any medications that alter blood sugar

Treatment and study plan

Primary outcomes

Beta-Cell Function measured as Disposition Index

Time frame: 1 day at screening

Disposition index will be calculated based on the results of the oral glucose tolerance test using minimal modeling (computer program)

Sponsors and collaborators

Lead sponsor

Children's Hospital Medical Center, Cincinnati

Other

Collaborators

National Center for Advancing Translational Sciences (NCATS)

Registry information

Official study title

Beta-Cell Function in Young Turner Syndrome Patients

Important dates

Study start: 2014
Primary completion: 2017
Study completion: 2017
First posted: Jun 11, 2014
Registry last updated: Aug 23, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed